{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:10:03Z","timestamp":1791817803815,"version":"4.3.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Radiation recall reaction is an acute inflammatory reaction confined to previously irradiated areas that are most commonly triggered by the administration of anti-cancer agents after radiotherapy. Radiation recall myositis is a relatively rare form of radiation recall reaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>Here we report a 29-year-old female patient who suffered from metastatic monophasic synovial sarcoma. 8.5 months after post-operative radiotherapy of the right thigh region, the patient suffered pain, edema, redness, and increased temperature locally on the right thigh. Physical exam showed red fixed skin, rigidity and severe tenderness of region, and thigh magnetic resonance imaging revealed dense edema areas at the addiction, semimembranous-semitendinous muscle, and superior part of the biceps femoris and vastus lateralis isointense on T1AG, hyperintense T2AG images. Based on these findings, the patient was diagnosed with pazopanib-induced radiation recall myositis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management &amp; outcome<\/jats:title>\n                    <jats:p>Pazopanib was stopped and pentoxifylline (2\u2009\u2009\u00d7\u2009400 mg), Vitamin E (3\u2009\u2009\u00d7\u2009400 mg), and methylprednisolone (2\u2009\u2009\u00d7\u20098 mg) were prescribed. After 1 month, complete relief of thigh pain and marked recovery of rigidity, as well as erythema, were achieved and no recurrence of radiation recall reaction-related symptoms was observed after the pazopanib rechallenge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Myositis is a relatively rare presentation of radiation recall reaction and physicians must be aware of the symptoms of the patients who are treated by radiotherapy and pazopanib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221125869","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T14:24:14Z","timestamp":1663251854000},"page":"980-985","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Radiation recall myositis with pazopanib in a patient with soft tissue sarcoma"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3529-4865","authenticated-orcid":false,"given":"Melike Peky\u00fcrek","family":"Varan","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of Health Sciences, Dr Lutfi K\u0131rdar Training and Research Hospital, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hande","family":"Turna","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul University-Cerrahpa\u015fa, Cerrahpa\u015fa Medical School, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazilet","family":"\u00d6ner Din\u00e7ba\u015f","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Istanbul University-Cerrahpa\u015fa, Cerrahpa\u015fa Medical School, \u0130stanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"key":"bibr1-10781552221125869","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0090"},{"key":"bibr2-10781552221125869","doi-asserted-by":"publisher","DOI":"10.1148\/73.2.175"},{"key":"bibr3-10781552221125869","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.146090"},{"key":"bibr4-10781552221125869","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2005.07.008"},{"key":"bibr5-10781552221125869","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103527"},{"key":"bibr6-10781552221125869","doi-asserted-by":"publisher","DOI":"10.1159\/000487478"},{"key":"bibr7-10781552221125869","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2010.02.012"},{"key":"bibr8-10781552221125869","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60651-5"},{"key":"bibr9-10781552221125869","unstructured":"FDA approved pazopanib tablets (VOTRIENT, a registered Trademark of GlaxoSmithKline) for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. Available from: http:\/\/www.fda.gov. (Accessed online August 26, 2022)."},{"key":"bibr10-10781552221125869","unstructured":"Assessment report Votrient (pazopanib) Procedure No: EMEA\/H\/C\/001141\/II\/0007. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/votrient-h-c-1141-ii-0007-epar-assessment-report-variation_en.pdf. (Accessed online August 26, 2022)."},{"key":"bibr11-10781552221125869","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.9764"},{"key":"bibr12-10781552221125869","doi-asserted-by":"publisher","DOI":"10.1159\/000355649"},{"key":"bibr13-10781552221125869","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.5366"},{"key":"bibr14-10781552221125869","doi-asserted-by":"crossref","first-page":"e29147","DOI":"10.1002\/pbc.29147","author":"Kosaka T","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"bibr15-10781552221125869","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr16-10781552221125869","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2013.811588"},{"key":"bibr17-10781552221125869","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2010.195"},{"key":"bibr18-10781552221125869","doi-asserted-by":"publisher","DOI":"10.1159\/000365918"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221125869","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221125869","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221125869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:32Z","timestamp":1777688852000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221125869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1177\/10781552221125869"],"URL":"https:\/\/doi.org\/10.1177\/10781552221125869","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]}}}